CN Patent

CN109331005A — 一种紫杉醇和氟酞嗪类btk抑制剂联合用药物组合物及其应用

Assigned to Nanjing Advanced Biomaterials And Process Equipment Research Institute Co Ltd · Expires 2019-02-15 · 7y expired

What this patent protects

本发明提供了一种紫杉醇和氟酞嗪酮类BTK抑制剂联合用药物组合物，其特征在于：包含活性成分和药学上可接受的辅料，所述的活性成分由紫杉醇和式(I)所示的BTK抑制剂组成，所述活性成分中紫杉醇和式(I)所示的BTK抑制剂的摩尔比为(0.14‑0.20)：1。该药物组合物可用于制备预防和/或治疗与布鲁顿酪氨酸激酶相关的疾病药物，治疗效果好。

USPTO Abstract

本发明提供了一种紫杉醇和氟酞嗪酮类BTK抑制剂联合用药物组合物，其特征在于：包含活性成分和药学上可接受的辅料，所述的活性成分由紫杉醇和式(I)所示的BTK抑制剂组成，所述活性成分中紫杉醇和式(I)所示的BTK抑制剂的摩尔比为(0.14‑0.20)：1。该药物组合物可用于制备预防和/或治疗与布鲁顿酪氨酸激酶相关的疾病药物，治疗效果好。

Drugs covered by this patent

Patent Metadata

Patent number
CN109331005A
Jurisdiction
CN
Classification
—
Expires
2019-02-15
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Advanced Biomaterials And Process Equipment Research Institute Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.